Saeid Shamsian. MD, a board-certified urologist in New York City, has been in practice since 1984. Dr. Saeid Shamsian concentrates on diseases of the kidneys, the bladder, and the ureter.
A new study finds that kidney-transplant patients may benefit from taking bisphosphonate drugs. In his systematic review and meta-analysis, researcher Craig Gordon, MD, of the Boston University School of Medicine states that bisphosphonates may increase bone mineral density in kidney transplant patients and that undergoing bisphosphonate therapy may be most beneficial within the first six months of the transplant. The study, however, wasn’t able to determine if the drugs could prevent fractures.
There is a great risk for the development of bone disorders in kidney transplant patients due to a combination of factors, including abnormal bone turnover from chronic kidney disease or post-transplantation tertiary hyperparathyroidism. As a result, bone mineral density drops within the first six months up until the 18th month, predisposing patients to fractures.
Dr. Gordon, however, also stated that taking bisphosphonates may result in adynamic bone disease, hence the therapy still cannot be universally recommended.